Cargando…
1170. Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review And Meta-analysis
BACKGROUND: Rotavirus causes 215,000 deaths from severe childhood diarrhea annually. Two rotavirus vaccines – a monovalent vaccine containing a single rotavirus strain (RV1) and a pentavalent vaccine containing 5 rotavirus strains (RV5) – are used in routine immunization programs of nearly 100 count...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643795/ http://dx.doi.org/10.1093/ofid/ofab466.1363 |
_version_ | 1784609935489761280 |
---|---|
author | Cates, Jordan Amin, Avnika Tate, Jacqueline Lopman, Ben Parashar, Umesh D |
author_facet | Cates, Jordan Amin, Avnika Tate, Jacqueline Lopman, Ben Parashar, Umesh D |
author_sort | Cates, Jordan |
collection | PubMed |
description | BACKGROUND: Rotavirus causes 215,000 deaths from severe childhood diarrhea annually. Two rotavirus vaccines – a monovalent vaccine containing a single rotavirus strain (RV1) and a pentavalent vaccine containing 5 rotavirus strains (RV5) – are used in routine immunization programs of nearly 100 countries. Concerns exist that rotavirus vaccines may be less effective against rotavirus strains not contained in the vaccines which could subsequently cause selective pressure and strain replacement. We estimated the vaccine effectiveness (VE) of RV1 and RV5 against vaccine (homotypic) and non-vaccine (partially and fully heterotypic) strains. METHODS: After conducting a systematic review, we meta-analyzed 31 case-control studies (N=27,293) conducted between 2006 and 2020 using a random-effect regression model. RESULTS: In high-income countries, RV1 VE was 10% lower against partially heterotypic (p-value=0.04) and fully heterotypic (p-value=0.10) compared to homotypic strains (homotypic VE: 90% [95% CI: 82, 94]; partially heterotypic VE: 79% [95% CI: 71, 85]; fully heterotypic VE: 80% [95% CI: 65, 88]; Figure 1). In middle-income countries, RV1 VE was 14 to 16% lower against partially heterotypic (p-value=0.06) and fully heterotypic (p-value=0.04) compared to homotypic strains (homotypic VE: 81% [95% CI: 69, 88]; partially heterotypic VE: 67% [95% CI: 54, 76]; fully heterotypic VE: 65% [95% CI: 52, 75]; Figure 1). Strain-specific RV5 VE differences were less pronounced (Figure 2). Limited data were available from low-income countries. Figure 1. Vaccine effectiveness by country income level and strain type, for RV1. [Image: see text] Figure 2. Vaccine effectiveness by country income level and strain type, for RV5. [Image: see text] CONCLUSION: Vaccine effectiveness of RV1 and RV5 was somewhat lower VE against non-vaccine than vaccine strains. Ongoing surveillance is crucial to continue long-term monitoring for strain replacement, particularly in low-income settings where data are limited. DISCLOSURES: All Authors: No reported disclosures |
format | Online Article Text |
id | pubmed-8643795 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-86437952021-12-06 1170. Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review And Meta-analysis Cates, Jordan Amin, Avnika Tate, Jacqueline Lopman, Ben Parashar, Umesh D Open Forum Infect Dis Poster Abstracts BACKGROUND: Rotavirus causes 215,000 deaths from severe childhood diarrhea annually. Two rotavirus vaccines – a monovalent vaccine containing a single rotavirus strain (RV1) and a pentavalent vaccine containing 5 rotavirus strains (RV5) – are used in routine immunization programs of nearly 100 countries. Concerns exist that rotavirus vaccines may be less effective against rotavirus strains not contained in the vaccines which could subsequently cause selective pressure and strain replacement. We estimated the vaccine effectiveness (VE) of RV1 and RV5 against vaccine (homotypic) and non-vaccine (partially and fully heterotypic) strains. METHODS: After conducting a systematic review, we meta-analyzed 31 case-control studies (N=27,293) conducted between 2006 and 2020 using a random-effect regression model. RESULTS: In high-income countries, RV1 VE was 10% lower against partially heterotypic (p-value=0.04) and fully heterotypic (p-value=0.10) compared to homotypic strains (homotypic VE: 90% [95% CI: 82, 94]; partially heterotypic VE: 79% [95% CI: 71, 85]; fully heterotypic VE: 80% [95% CI: 65, 88]; Figure 1). In middle-income countries, RV1 VE was 14 to 16% lower against partially heterotypic (p-value=0.06) and fully heterotypic (p-value=0.04) compared to homotypic strains (homotypic VE: 81% [95% CI: 69, 88]; partially heterotypic VE: 67% [95% CI: 54, 76]; fully heterotypic VE: 65% [95% CI: 52, 75]; Figure 1). Strain-specific RV5 VE differences were less pronounced (Figure 2). Limited data were available from low-income countries. Figure 1. Vaccine effectiveness by country income level and strain type, for RV1. [Image: see text] Figure 2. Vaccine effectiveness by country income level and strain type, for RV5. [Image: see text] CONCLUSION: Vaccine effectiveness of RV1 and RV5 was somewhat lower VE against non-vaccine than vaccine strains. Ongoing surveillance is crucial to continue long-term monitoring for strain replacement, particularly in low-income settings where data are limited. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2021-12-04 /pmc/articles/PMC8643795/ http://dx.doi.org/10.1093/ofid/ofab466.1363 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Poster Abstracts Cates, Jordan Amin, Avnika Tate, Jacqueline Lopman, Ben Parashar, Umesh D 1170. Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review And Meta-analysis |
title | 1170. Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review And Meta-analysis |
title_full | 1170. Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review And Meta-analysis |
title_fullStr | 1170. Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review And Meta-analysis |
title_full_unstemmed | 1170. Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review And Meta-analysis |
title_short | 1170. Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review And Meta-analysis |
title_sort | 1170. do rotavirus strains affect vaccine effectiveness? a systematic review and meta-analysis |
topic | Poster Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643795/ http://dx.doi.org/10.1093/ofid/ofab466.1363 |
work_keys_str_mv | AT catesjordan 1170dorotavirusstrainsaffectvaccineeffectivenessasystematicreviewandmetaanalysis AT aminavnika 1170dorotavirusstrainsaffectvaccineeffectivenessasystematicreviewandmetaanalysis AT tatejacqueline 1170dorotavirusstrainsaffectvaccineeffectivenessasystematicreviewandmetaanalysis AT lopmanben 1170dorotavirusstrainsaffectvaccineeffectivenessasystematicreviewandmetaanalysis AT parasharumeshd 1170dorotavirusstrainsaffectvaccineeffectivenessasystematicreviewandmetaanalysis |